Main Uses and Therapeutic Benefits of Bevacizumab

Bevacizumab is a targeted therapeutic agent that is used in managing several advanced and metastatic malignancies. It is approved for use against several advanced and metastatic conditions, and is considered relevant in contexts involving heightened systemic burden.

---

Key Areas of Use in Advanced Cancer

This medicine may be used as part of symptomatic management across conditions presenting with systemic or localized discomfort. It is considered relevant in clinical settings that involve acute or unstable symptom patterns for conditions such as colorectal cancer, non-small cell lung cancer, ovarian, fallopian tube, primary peritoneal cancer, and cervical cancer. It is also applied in situations involving kidney cancer and certain brain tumors.

Quick Fact: Relief for symptoms that interfere with daily functioning.

Supporting Symptom Management and Patient Comfort

Bevacizumab contributes to easing the overall symptom load, which in turn helps manage symptom clusters that may become intense or disruptive. It is commonly used when short-term symptomatic assistance is needed, providing supportive relief that helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability during periods of heightened symptoms. The medicine supports general well-being during symptomatic phases.

Assistance in Disease Stabilization

Used across domains where additional symptomatic support is needed, this medicine plays a role in managing conditions characterized by periods of heightened symptoms. In situations where patients experience increased discomfort, this medicine is considered relevant for easing symptoms that create noticeable physiological strain and helping patients maintain a sense of stability when symptoms are more noticeable.

Regulatory References

1. European Medicines Agency therapeutic overview

This section outlines patient eligibility for bevacizumab strictly based on official regulatory labeling. Use is generally established for adult patients with specific approved cancer indications.

Contraindicated Populations

Treatment is absolutely prohibited for certain groups:

• Patients with known hypersensitivity to bevacizumab, its components, or to Chinese Hamster Ovary (CHO) cell products.
• Women who are pregnant.

Conditions Requiring Discontinuation

Use must be permanently discontinued if certain severe complications occur, including Gastrointestinal (GI) perforation, severe hemorrhage (e.g., Grade 3 or 4 bleeding), or a hypertensive crisis.

Eligibility-Related Restrictions

Population	Regulatory Status
Surgical Patients	Must be withheld for at least 28 days prior to elective surgery and for 28 days post-surgery, or until the wound is fully healed.
Pregnancy/Lactation	Contraindicated in pregnancy; not recommended during breastfeeding (and for 6 months after the last dose). Contraception is required during treatment and for 6 months post-treatment.
Paediatric Population (<18 years)	Safety and efficacy have not been established.
Hepatic/Renal Impairment	Safety and efficacy have not been studied.

Eligibility is defined by the absence of contraindications, the clinical status of the patient (e.g., wound healing), and the sufficiency of established efficacy data for the specific age group.

Interactions with other medicines and products

Bevacizumab (Бевацизумаб) has a regulatory interaction profile that emphasizes pharmacodynamic (PD) and receptor-mediated pharmacokinetic (PK) risks, which is characteristic of a monoclonal antibody.

Documented Interaction Patterns

Interaction Type	Interacting Agent or Condition	Official Regulatory Statement
PD Risk Reinforcement	Anthracyclines (e.g., Doxorubicin)	Associated with an increased risk of Congestive Heart Failure (CHF).
PD Risk Reinforcement	Sunitinib	Co-administration is not recommended due to an increased risk of microangiopathic hemolytic anemia (MAHA).
PK Exposure Alteration	FcRn-Binding Agents	May result in decreased systemic exposure of Bevacizumab due to receptor competition.
Administration Timing	Elective Surgery	Treatment must be withheld for at least 28 days prior and may not be resumed until the surgical wound is fully healed.

Officially Noted Absence of Interaction

The regulatory profile reports no clinically relevant interaction warnings pertaining to the major metabolic pathways, such as CYP enzymes, and no known interactions with food, alcohol, or herbal products are documented in the official labeling.

This profile is defined by mandatory timing restrictions for surgical procedures and warnings for specific anti-cancer combination therapies, establishing clear constraints based on co-administration risks defined by government regulatory authorities.

How Bevacizumab Works

Bevacizumab is a humanized monoclonal antibody whose mechanism relies on the neutralization of the soluble signaling protein Vascular Endothelial Growth Factor A (VEGF-A). By binding to circulating VEGF-A, the antibody sequesters the ligand, preventing it from interacting with and activating its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells.

This molecular blockade arrests the angiogenesis cascade, suppressing the intracellular signaling sequences that drive endothelial cell proliferation and migration. This inhibition of new vessel formation leads to a reduction in Microvessel Density (MVD), functionally restricting the supply of oxygen and nutrients to the affected tissue mass.

The mechanism also affects existing vasculature, inducing vascular normalization. This structural change reduces vessel permeability and lowers elevated interstitial fluid pressure, which is theorized to facilitate the delivery of co-administered therapeutic agents. The overall physiological effect is a functional constraint on the development of vascular infrastructure necessary for tissue expansion. The mechanism is subject to limitation by physiological adaptation, such as HIF-1α mediated signaling, which can create alternative pro-angiogenic pathways.

How Bevacizumab is Used: Official Administration Guidelines

Bevacizumab is administered exclusively via Intravenous (IV) infusion and must not be given as an IV push or bolus. The dosing follows a cyclic schedule, typically occurring once every two or three weeks. The precise dose is weight-based (mg/kg) and determined by the specific treatment regimen being followed.

---

Procedural Requirements

Requirement	Detail
Route/Method	Intravenous infusion only; must not be administered as an IV push or bolus.
Preparation	Must be diluted in 100 mL of 0.9% Sodium Chloride Injection, USP; mixing with dextrose solutions is prohibited.
Infusion Rate	The first dose must run over 90 minutes; subsequent doses may be shortened to 30 minutes if tolerated.
Surgical Timing	Initiation is restricted until at least 28 days following major surgery and until the surgical wound is fully healed.

---

The official usage protocol requires specific procedural steps. For instance, the exact dose must be diluted using aseptic technique in 0.9% Sodium Chloride solution. Treatment duration generally continues until disease progression or unacceptable toxicity. There is no relevant use established for the pediatric population in the approved indications, and there are no recommended dose reductions for managing adverse reactions, which require withholding or discontinuing treatment instead. This protocol establishes a standardized, non-variable method for the drug’s physical delivery.

Research evidence / Overview of studies for Bevacizumab

Bevacizumab has been evaluated across multiple cancer types through large, comparative studies that contributed to the evidence base for its use. This overview describes the structure of the research evidence, what was examined, and where research remains limited, without offering clinical recommendations.

---

Evidence for use in Metastatic Colorectal Cancer

Research exploring the use of bevacizumab in metastatic colorectal cancer (mCRC) included several large, international Phase III Randomized Controlled Trials (RCTs). These studies typically examined bevacizumab when combined with standard chemotherapy regimens, comparing this combination to chemotherapy given alone. Studies monitored Overall Survival (OS) and Progression-Free Survival (PFS) endpoints and documented patterns related to these outcomes for the groups receiving the combination therapy compared to the groups receiving chemotherapy alone. Data does not support its use in the adjuvant setting (after initial surgery).

---

Evidence for use in Non-Small Cell Lung Cancer (NSCLC)

Studies focused specifically on patients with advanced non-squamous histology. Researchers used pivotal Phase III RCTs to explore outcomes when the medicine was evaluated alongside platinum-based chemotherapy. Research describes patterns related to both OS and PFS when the medicine was evaluated alongside the standard chemotherapy regimen in the studies. A key limitation is that the research applies only to patients with non-squamous histology; data for the squamous subtype remain insufficient due to their exclusion from the main studies.

---

Evidence for use in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Research utilized large Phase III RCTs in both the first-line setting and for recurrent disease. The primary outcome was Progression-Free Survival (PFS), with trials reporting patterns of measured PFS durations. While Overall Survival (OS) was also evaluated, the findings were mixed, with some studies describing documented differences in OS in certain recurrent settings but with less consistent patterns observed in the newly diagnosed settings.

---

What is still uncertain about Bevacizumab Research

Research highlights that data for certain groups remain insufficient, especially for patients with squamous NSCLC and those with significant central nervous system involvement. Findings were mixed or did not show a clear difference in outcomes for the Overall Survival endpoint in some key settings, such as newly diagnosed glioblastoma. The evidence quality varies across studies, with some initial evidence derived from smaller Phase II data. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References Bevacizumab in ovarian cancer: A critical review of phase III studies (Discusses OS and PFS in recurrent settings)

Common questions about Бевацизумаб (FAQ)

---

Q: Это лекарство используют как самостоятельное лечение или всегда в комбинации?

A: Regulatory documents describe the medicine's use in combination with chemotherapy for most approved indications. This strategy is typical for treating various metastatic cancers. Some studies have examined its use as a single agent in specific settings, but approved use is generally in a combination regimen.

---

Q: Можно ли принимать Бевацизумаб, если у меня есть проблемы с сердцем?

A: Regulatory warnings indicate that events consistent with Congestive Heart Failure (CHF) have been reported in patients receiving this medicine. This is particularly noted in patients who have pre-existing risk factors, including prior cardiovascular disease. Official guidance indicates caution when considering treatment for patients with clinically significant pre-existing heart problems.

---

Q: Что такое синдром обратимой задней лейкоэнцефалопатии (PRES), связанный с Бевацизумабом?

A: The official product labeling describes Posterior Reversible Encephalopathy Syndrome (PRES) as a rare, serious neurological condition that has been reported in patients treated with this medicine. PRES is characterized by symptoms such as headache, seizures, confusion, and changes in vision, and it is usually diagnosed using brain imaging.

---

Q: Как долго Бевацизумаб остается в организме после последней инфузии?

A: Based on pharmacokinetic studies, the medicine's mean terminal half-life is estimated to be approximately 20 days, though this can vary widely among individuals. Regulatory labeling notes that women of reproductive potential are advised to use effective contraception for 6 months after the last dose, which reflects the clearance period.

---

Q: Какова продолжительность курса лечения Бевацизумабом?

A: The treatment duration is generally described in regulatory information as continuing until there is disease progression or the occurrence of side effects that necessitate discontinuation. For certain cancer types, like ovarian cancer, specific approved regimens may have a defined duration, such as 15 months.

---

Q: Может ли Бевацизумаб влиять на зрение?

A: The medicine’s adverse reaction lists include general eye disorders and sometimes more specific reports like blurred vision. Additionally, serious but rare conditions like PRES (Posterior Reversible Encephalopathy Syndrome) can present with visual disturbances or even blindness, according to regulatory documents.

---

Q: Существуют ли долгосрочные побочные эффекты после прекращения приема Бевацизумаба?

A: Long-term effects are generally not fully documented in regulatory summaries. However, the medicine is associated with a risk of temporary or persistent ovarian failure in premenopausal women. In clinical studies, some women demonstrated recovery of ovarian function after stopping treatment.

---

Q: Как часто нужно сдавать анализы крови во время лечения?

A: Official guidance emphasizes the need for routine blood pressure monitoring during therapy. Monitoring is also required for conditions like proteinuria and hemorrhage, which rely on laboratory assessments. Specific schedules for monitoring tests are determined by the medical team and based on the individual treatment plan.

---

Q: Может ли алкоголь взаимодействовать с Бевацизумабом?

A: Official regulatory labeling reports no known interactions with alcohol are documented. However, patients should be mindful that alcohol consumption may potentially worsen some of the medicine's common side effects, such as headache or fatigue.

---

Q: Что такое «биосимиляры» Бевацизумаба, и чем они отличаются от оригинала?

A: Biosimilars are biological products determined by regulatory agencies to be highly similar to the approved original medicine, with no clinically meaningful differences in terms of safety or effectiveness. They are not structurally identical copies but are approved after showing they perform essentially the same as the original reference product.

---

Q: Помогает ли Бевацизумаб при метастазах?

A: Yes, the medicine is approved and researched for use in the treatment of various metastatic cancers as part of its official indications. Examples include metastatic colorectal cancer, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical carcinoma.

---

Q: Как понять, что лечение Бевацизумабом перестало работать?

A: The medicine is generally continued until there is evidence of disease progression or the development of side effects that necessitate discontinuation. Disease progression is a clinical finding, typically determined by specialized medical imaging or other standardized clinical assessments ordered by the medical team.

---

Q: Какие меры предосторожности необходимо соблюдать после инфузии Бевацизумаба?

A: The regulatory guidance includes precautions regarding surgery, stating the medicine should be withheld for at least 28 days before and after major procedures, or until the wound is fully healed. The risk of infusion-related reactions is also noted, with the potential for them to occur up to 24 hours after the infusion.

---

Q: Может ли Бевацизумаб влиять на менструальный цикл?

A: Official information indicates that clinical studies have noted an increased risk of ovarian failure in premenopausal women receiving the medicine. Ovarian failure involves the loss of ovarian function and is associated with significant changes to the menstrual cycle.

---

Q: Возможно ли развитие устойчивости (резистентности) к Бевацизумабу со временем?

A: Research indicates that the long-term effectiveness of the medicine may be limited by the development of drug resistance in tumor tissue. This effect is sometimes attributed to the tumor finding alternative ways to grow blood vessels to bypass the medicine's blockage.

---

Q: Какие обследования проводятся перед началом лечения Бевацизумабом?

A: Regulatory guidance requires that pre-existing hypertension must be adequately controlled before starting treatment. Therefore, monitoring of blood pressure and an assessment of wound healing status are necessary initial steps. Patients must not have open or unhealed surgical wounds at the time of treatment initiation.

How to Store and Dispose of Bevacizumab

Storage Requirements

Bevacizumab concentrate must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F to 46 F). It is essential that the vials are not frozen and must be kept in their original outer carton to protect the solution from light. The medicine must be stored out of the sight and reach of children.

Post-Dilution Stability

Once the solution is diluted for infusion, it is chemically stable for 24 hours (at up to 30 C). However, use should be immediate from a microbiological standpoint, or the diluted solution may be stored at 2 C to 8 C for up to 24 hours if prepared under aseptic conditions.

Disposal Instructions

Unused bevacizumab and waste material must be disposed of in accordance with local requirements for cytotoxic/hazardous medicinal products. Do not discard the medicine in household trash or pour it down a drain.